Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Skyworks Solutions Inc (SWKS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Skyworks Solutions Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $299.53 (market cap $39.89B), while Skyworks Solutions Inc trades at $59.37 (market cap $9.08B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 4.4× Skyworks Solutions Inc's market cap, and Skyworks Solutions Inc pays a 4.7% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | SWKS | |
|---|---|---|
Market Cap | $39.89B | $9.08B |
Sector | Health | Technology |
52-Week High | $491.22 | $83.40 |
52-Week Low | $278.09 | $52.50 |
Enterprise Value | $38.15B | $8.85B |
Dividend Yield | — | 4.7% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
SWKS trades at $60.36, up 0.68% on the day, with a bearish technical signal but bullish oscillators. The company reported Q1 2026 EPS of $1.15, beating estimates, and maintains a dividend. Revenue has trended down from $5.5B in 2022 to $4.1B in 2025, though net income margin remains positive at 8.93%. Recent news highlights potential in smartphone chips and AI infrastructure.
The outlook is mixed: strong analyst buy consensus (60%) and a $72.56 price target suggest upside, but declining revenue, legal investigations, and a bearish technical trend pose risks. The stock's valuation at a P/E of 25.16 appears reasonable if growth stabilizes, but investor caution is warranted amid competitive and execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Skyworks Solutions Inc
Skyworks Solutions produces semiconductors for wireless handsets and other devices that are used to enable wireless connectivity. Its main products include power amplifiers, filters, switches, and integrated front-end modules that support wireless transmissions. Skyworks' customers are mostly large smartphone manufacturers, but the firm also has a growing presence in nonhandset applications such as wireless routers, medical devices, and automobiles.
Read more on SWKS →
